Wilkinson T
Roche Discovery Welwyn, Department of Biochemistry, Welwyn Garden City, Hertfordshire, UK.
Curr Opin Investig Drugs. 2001 Nov;2(11):1516-22.
Hepatitis C virus (HCV) infection is a major health crisis worldwide. Current treatment requires combination therapy with interferon-alpha and ribavirin. The low efficacy and poor tolerability of this therapeutic regimen has driven the search for safer and more effective medicines. This search has led to intense research efforts which have enhanced our understanding of HCV biology and to the development of a number of strategies for identifying new antiviral agents. At the same time, efforts have been directed towards improving the efficacy and tolerability of existing therapies. Recent developments in the area of modified interferons and research on virus-encoded and host drug discovery targets are reviewed here. Advances in the field of improved interferon-based treatments and the use of new antiviral agents in clinical trials gives cause for optimism in the clinical management of HCV infections.
丙型肝炎病毒（HCV）感染是全球范围内的重大健康危机。目前的治疗需要使用α干扰素和利巴韦林进行联合治疗。这种治疗方案疗效低且耐受性差，促使人们寻找更安全、更有效的药物。这一探索引发了大量的研究工作，增进了我们对HCV生物学的理解，并推动了多种识别新型抗病毒药物策略的发展。与此同时，人们致力于提高现有疗法的疗效和耐受性。本文综述了改良干扰素领域的最新进展以及病毒编码和宿主药物发现靶点的研究。基于干扰素的改良治疗领域的进展以及新型抗病毒药物在临床试验中的应用，为丙型肝炎病毒感染的临床管理带来了乐观的前景。
